Table 1

Primary performance measures for the Improving Care for Cardiovascular Disease in China-atrial fibrillation project

ReferenceTitle of performance measureProportion, %
(numerator/denominator)
7, 22 Proportion of patients with non-valvular AF in whom assessment of thromboembolic risk23.6 (5384/22 864)
7, 22 Proportion of AF patients with indication prescribed an anticoagulant drug at discharge*42.3 (6413/15 150)
7, 22 Proportion of patients discharged on warfarin who have PT/INR follow-up planned at discharge87.2 (7721/8857)
7, 22 Proportion of AF patients with indications receiving ACEI/ARB at discharge†53.1 (1794/3382)
7, 22 Proportion of AF patients with indication prescribed a beta-blocker at discharge‡57.0 (1245/2184)
7 Proportion of AF patients with indication prescribed a statin at discharge§61.2 (8524/13 925)
Composite scores of primary performance measures46.8 (31 081/66 362)
  • *Indications refer to non-valvular AF patients with CHA2DS2-VASc≥2.

  • †Indications refer to AF patients with acute myocardial infarction; or coronary heart disease with comorbidity of hypertension, diabetes mellitus or chronic kidney disease; or left ventricular ejection fraction <40% according to the case records.

  • ‡Indications refer to AF patients with heart failure.

  • §Indications refer to AF patients with coronary heart disease, ischaemic stroke/transient ischaemic attack, peripheral vascular disease or diabetes mellitus.

  • ACEI, ACE inhibitor; ARB, angiotensin receptor blocker.; INR, international normalised ratio; PT, prothrombin time.